<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160081</url>
  </required_header>
  <id_info>
    <org_study_id>113564</org_study_id>
    <nct_id>NCT01160081</nct_id>
  </id_info>
  <brief_title>Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis</brief_title>
  <official_title>Sero-prevalence of Hepatitis A Varicella-Zoster Virus, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis in Mexico</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the seroprevalence of Hepatitis A Virus (HAV),
      Varicella-Zoster virus (VZV), Cytomegalovirus (CMV), Herpes Simplex (HSV) and Bordetella
      pertussis (BP)infections in Mexico.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to document the epidemiological changes in the sero-prevalence of Hepatitis A, Human
      simplex virus (1 and 2), Varicella-Zoster virus and Cytomegalovirus infections, we propose to
      conduct a population based, seroprevalence, cross-sectional study, in Mexico. This will allow
      the identification of susceptible populations, which in turn, will serve as evidence for the
      elaboration of recommendations for the prevention of Hepatitis A, Human simplex virus,
      Varicella-Zoster virus and Cytomegalovirus infection in the region.

      This study was conducted using data and serum samples from a random sample of subjects that
      participated in the 2006 National Health and Nutrition Survey.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HAV seropositivity status: Subjects with anti-HAV antibody titers &gt;= assay cut-off.</measure>
    <time_frame>6 to 10 months from study initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Pertussis Toxin seropositivity status for IgG and IgA: Subjects with anti-Pertussis Toxin antibody titers &gt;= assay cut-off for IgG, Subjects with anti-Pertussis Toxin antibody titers &gt;= assay cut-off for IgA</measure>
    <time_frame>6 to 10 months from study initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-VZV seropositivity status: Subjects with anti-VZV antibody titers &gt;= assay cut-off</measure>
    <time_frame>6 to 10 months from study initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-CMV seropositivity status: Subjects with anti-CMV antibody titers &gt;= assay cut-off</measure>
    <time_frame>6 to 10 months from study initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HSV seropositivity status (defined as the percentage of subjects with anti-HSV 1 and 2 titers &gt;= assay cut-off): Subjects with anti-HSV antibody titers &gt;= assay cut-off</measure>
    <time_frame>6 to 10 months from study initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in HAV, VZV, CMV , HSV and BP seropositivity rates according to socioeconomic status, age group, gender, region, risk group, area and pertussis vaccination status (only for BP analysis)</measure>
    <time_frame>6 to 10 months from study initiation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3658</enrollment>
  <condition>Viral Hepatitis Vaccines</condition>
  <condition>Hepatitis A</condition>
  <condition>Cytomegalovirus</condition>
  <condition>Varicella-Zoster Virus</condition>
  <condition>Bordetella Pertussis Infection</condition>
  <condition>Herpes Simplex (1 and 2)</condition>
  <arm_group>
    <arm_group_label>National Health and Nutrition Survey 2006 (ENSANUT 2006)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Serum sample</intervention_name>
    <description>Serum samples collected</description>
    <arm_group_label>National Health and Nutrition Survey 2006 (ENSANUT 2006)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include a random sample of 4000 subjects of subjects who
        participated in the 2006 National Health and Nutrition Survey (ENSANUT).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Previously enrolled subjects aged &gt;= 1 to 70 years for National Health and Nutrition
        Survey 2006 in Mexico, with previously obtained informed consent

        Exclusion Criteria:

          -  Information required for the study is not available or incomplete.

          -  Inadequate or insufficient serum sample to detect viral agents required for the study.

          -  Serum sample wrongly identified.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>January 22, 2011</last_update_submitted>
  <last_update_submitted_qc>January 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>E.D. Derilus; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

